Takeda Pharmaceutical Ltd ADR (TAK)

Chasing high yields alone will ruin an income investor’s returns, so we look at these picks that offer a balance of stability and dividend income growth.

5 of the Best Pharmaceutical Stocks to Buy Right Now

By David Moadel, InvestorPlace Contributor Sep 10, 2020

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

Blackstone to Buy Takeda Pharmaceutical Consumer Unit

By William White, InvestorPlace Writer Aug 24, 2020

Blackstone (BX) will be acquiring Takeda Consumer Healthcare, which is the consumer division of Takeda Pharmaceutical (TAK).

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

By Louis Navellier and the InvestorPlace Research Staff Jun 9, 2020

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

Takeda to acquire rights to Hutchmed's cancer drug fruquintinib for $400M upfront

From Seeking Alpha Jan 23, 2023

Takeda (TAK) signed a licensing agreement with Hutchmed (China) (HCM) to develop and commercialize oral cancer drug fruquintinib outside of mainland China, Hong Kong and Macau.Under...

Arrowhead stock dips ~15% amid phase 2 data for liver disease drug fazirsiran

From Seeking Alpha Jan 9, 2023

Takeda (TAK) and Arrowhead Pharmaceuticals (ARWR) reported data from a phase 2 trial of fazirsiran (TAK-999/ARO-AAT) to treat liver disease associated with alpha-1 antitrypsin...

Takeda succeeds in Phase 3 trial for clotting disorder candidate (NYSE:TAK)

From Seeking Alpha Jan 5, 2023

Takeda (TAK) announced Thursday that its candidate for clotting disorder, congenital thrombotic thrombocytopenic purpura (cTTP), led to positive Phase 3 results. Read the full story here.

SDGR stock, VTYX stock rise after Takeda deal for psoriasis candidate (NASDAQ:SDGR)

From Seeking Alpha Dec 13, 2022

Schrödinger (SDGR) and Ventyx Biosciences (VTYX) rallied Tuesday after Takeda (TAK) agreed to pay $4B upfront to acquire a company developing a TYK2 inhibitor. Read full story here.

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday

From The Motley Fool Nov 2, 2022

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

From Benzinga May 11, 2022

Takeda Pharmaceutical Ltd ADR (TAK)

7 Sorry Dividend Stocks to Sell in February Before It’s Too Late

7 Dividend Stocks to Sell Pronto Before a Painful Downturn

7 Stocks Under $15 to Buy and Hold Forever

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Takeda Pharmaceutical Ltd ADR (TAK)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

TAK Stock Predictions, Articles, and Takeda Pharmaceutical Ltd ADR News

Subscriber Sign in